DB09305ExperimentalSmall molecule
Aptazapine (CGS-7525A) was a tetracyclic antidepressant developed in the 1980s. Aptazapine had noradrenergic and specific serotonergic activity. It antagonised α2 adrenergic receptors approximately 10 times more effectively than mianserin, antagonised... Although Aptazapine reached clinical trials, it was never marketed.
- Primary indication
- Investigated for the treatment of depression.Curator reviewed
- Formula / weight
- C16H19N3 · 253.349 g/mol (avg)
- Code names
- CGS-7525A
Resolves to
Structure
InChIKey
MNHDDERDSNZCCK-UHFFFAOYSA-NSMILESCN1CCN2C(C1)C1=CC=CN1CC1=C2C=CC=C1What you can answer from here — as of August 30, 2026
Which companies are running trials of Aptazapine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account